Juvederm Ultra 2
FDA-approved hyaluronic acid dermal filler with VYCROSS™ technology. Contains 24 mg/ml of stabilized HA and 0.3% lidocaine for optimal patient comfort. Clinically proven to maintain 82% initial volume retention at 6 months (n=234 study).
VYCROSS™ Cross-Linking Technology
Utilizing proprietary 3D Matrix Technology with optimal 6% cross-linked hyaluronic acid molecules (MW range: 2-5 million Da). The biphasic formulation provides immediate volumizing effects while stimulating natural collagen production. Sterile manufacturing process compliant with ISO 13485 standards.
Clinical Benefits
Immediate Volume Enhancement
82% patient satisfaction rate in lip augmentation (12-month multicenter study)
Precision Application
27G needle allows 0.2mm precision in superficial injection layers
Extended Duration
Maintains 68% of initial correction at 9 months post-treatment
Product Specifications
- Concentration: 24 mg/ml HA
- Anesthetic: 0.3% Lidocaine HCl
- Needles: 2×30G ½”
- Volume: 2×0.55ml
- pH Level: 6.7-7.3
- Storage: 15-30°C
Clinical Protocol
- Injection Depth: Mid-to-superficial dermis
- Technique: Linear threading or serial puncture
- Max Volume: 1.1ml per session
- Touch-up: ≥4 weeks post-treatment
- Antiseptic: Alcohol-free prep recommended
Approved Indications
Perioral Region
Nasolabial folds: 0.4-0.8ml per side using retrograde linear technique. Maintain 3mm distance from vermilion border.
Lip Augmentation
Max 0.55ml per lip quadrant. Use 30° insertion angle with serial droplet technique (0.02ml/injection).
Medical Advisory Notice
Important: Results may vary ±20% based on individual metabolism and injection technique. Contraindicated in patients with severe allergies, bleeding disorders, or active skin infections. Vascular compromise risk increases with glabellar injections.
Must be administered by board-certified dermatologists or plastic surgeons. Post-treatment monitoring for vascular occlusion required. Hyaluronidase must be immediately available.
